insitro
A company applying machine learning to drug discovery and development.
Contents11 sections
Key facts
Company and Platform
Based in South San Francisco, insitro combines population genetics with automated cellular experiments to identify disease targets and design drug candidates.[1]
The company describes Virtual Human as an AI system for causal disease biology and TherML as its engine for designing small molecules, oligonucleotides, and complex biologics.[1]
2018Formation
October 28, 2020BMS Collaboration
The company entered a five-year collaboration with Bristol Myers Squibb on ALS and frontotemporal dementia.[4]
March 15, 2021Series C
insitro announced a $400 million Series C led by CPP Investments to expand its platform and pipeline.[2]
October 14, 2025BMS Extension
The partners extended their collaboration for one year to use ChemML to design small molecules for an identified ALS target, with up to $20 million in potential new funding.[5]
January 12, 2026Acquisition Plan and TherML
The company announced plans to acquire CombinAbleAI and launched TherML, incorporating biologics design capabilities. Closing was then expected later that month.[6]
October 6, 2026TuneLab Models
Small-molecule pharmacokinetic prediction models developed with Lilly became available to selected biotech companies through TuneLab.[7]
October 15, 2026AstraZeneca Collaboration
The partners agreed to research MASH and cardiomyopathies, with a $40 million upfront payment to insitro.[8]
Research Pipeline
The published pipeline covers liver fat and fibrosis, obesity, ALS, and dry age-related macular degeneration, with programs including CTRO-1013, CTRO-1029, and CTRO-2018.[9]
Related Organizations, Websites, and Public Accounts
insitro: Official link: https://www.insitro.com/ (opens in a new window)[1]
X: Public account: https://x.com/insitro (opens in a new window)[10]
LinkedInLinkedInLinkedIn is a social networking platform for professionals. It was founded in 2002 by Reid Hoffman and others, launched in 2003, and listed on the New York Stock Exchange in 2011; after Microsoft acquired it for approximately $26.2 billion in 2016, it became a wholly owned Microsoft subsidiary. Its revenue comes from membership subscriptions, advertising, and recruitment solutions.Open the full entry: Public profile: https://www.linkedin.com/company/insitro/ (opens in a new window)[11]
Sources
- insitro (opens in a new window)
- insitro Raises $400 Million in Series C Financing (opens in a new window)
- Daphne Koller – insitro (opens in a new window)
- insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (opens in a new window)
- insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform (opens in a new window)
- insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design (opens in a new window)
- insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab (opens in a new window)
- insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies (opens in a new window)
- Pipeline – insitro (opens in a new window)
- insitro (@insitro) / X (opens in a new window)
- insitro | LinkedIn (opens in a new window)